Hepatera

Hepatera is a clinical-stage biotech advancing a novel NTCP inhibitor for hepatitis B and D, with its lead program having achieved regulatory designations in Russia, the EU, and as a Breakthrough Therapy from the FDA. The company leverages a unique mechanism of action that blocks viral entry, demonstrating superiority over existing interferon-based therapies in clinical trials. Backed by Russian state initiatives and key European academic and industry partners, Hepatera is positioned to address a significant unmet need in viral hepatitis. Its primary candidate has treated over 550 patients in clinical studies and is progressing toward broader commercialization.

Development of inhibitors targeting the sodium taurocholate co-transporting polypeptide (NTCP) to block cellular entry of Hepatitis B and D viruses.

In HDV, Hepatera's (partnered) asset was first-to-market but now faces emerging competition from other late-stage direct-acting antiviral candidates. In the broader HBV functional cure landscape, it competes with numerous large pharmaceutical and biotech companies pursuing diverse mechanisms including siRNA, capsid inhibitors, and immune modulators.